- In November 2022, Danaher announced a strategic partnership with Duke University to establish its first Danaher Beacon for Gene Therapy Innovation. This initiative focuses on investing in product innovation and advancing external R&D, with an emphasis on genomic medicine, precision diagnostics, next-generation biomanufacturing, human systems, and data sciences
- In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics, a Poland-based company specializing in innovative medical diagnostic and healthcare technologies. This acquisition expanded Bio-Rad's product portfolio and strengthened its global market presence
- In April 2021, Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. announced the completion of patient enrollment for the Follicular Lymphoma Primary Efficacy Population in the global Phase 2 TIDAL study. This milestone marks a key advancement in their efforts to evaluate new therapeutic options for follicular lymphoma treatment
- In February 2021, Bristol Myers Squibb received FDA approval for its CAR-T cell therapy, Breyanzi, aimed at treating large B-cell lymphoma. This therapy is intended for patients who have relapsed or not responded to two prior types of systemic treatments, offering new hope for difficult-to-treat cases
- In December 2020, AstraZeneca announced that its cancer drug Calquence showed positive results in treating mantle cell lymphoma patients during its Phase 2 clinical trial. The success of the trial highlighted the drug's potential in providing a new treatment option for this rare and aggressive cancer
- In June 2020, Kyowa Kirin introduced their drug POTELIGO in Germany for the treatment of rare cancers such as mycosis fungoides and Sézary syndrome in adult patients. The drug's commercial availability aims to address the needs of patients with these difficult-to-treat skin cancers
